Zobrazeno 1 - 10
of 83
pro vyhledávání: '"Scot Ebbinghaus"'
Autor:
Tian Zhang, Patrick M Forde, Ryan J Sullivan, Elad Sharon, Elizabeth Barksdale, Wendy Selig, Scot Ebbinghaus, Gina Fusaro, Damla Gunenc, Dena Battle, Robyn Burns, Marc S Hurlbert, Mark Stewart, Michael B Atkins
Publikováno v:
Journal for ImmunoTherapy of Cancer. 11:e006555
With multiple PD-(L)1 inhibitors approved across dozens of indications by the US Food and Drug Administration, the number of patients exposed to these agents in adjuvant, first-line metastatic, second-line metastatic, and refractory treatment setting
Autor:
Brian R. Gastman, Ahmad A. Tarhini, Robert M. Conry, Pauline Funchain, Karl D. Lewis, Antoni Ribas, Sapna Pradyuman Patel, Hongli Li, Kenneth F. Grossmann, Magdalena Kovacsovics-Bankowski, Teresa M. Petrella, Elizabeth I. Buchbinder, Nageatte Ibrahim, Ragini R. Kudchadkar, James Moon, Douglas B. Johnson, Thach-Giao Truong, Larissa A. Korde, Michael V. Knopp, Kari Kendra, Elad Sharon, Scot Ebbinghaus, Bartosz Chmielowski, Vernon K. Sondak, John M. Kirkwood, Zeynep Eroglu, Nikhil I. Khushalani, Justine V. Cohen, Megan Othus, Krishna S Gunturu, Sama Ahsan
Publikováno v:
Cancer discovery, vol 12, iss 3
Cancer Discov
Cancer Discov
We conducted a randomized phase III trial to evaluate whether adjuvant pembrolizumab for one year (647 patients) improved recurrence-free survival (RFS) or overall survival (OS) in comparison with high-dose IFNα-2b for one year or ipilimumab for up
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be95c3ea01eedee0bb4c9a85fc5d89b2
https://escholarship.org/uc/item/8x51z8rb
https://escholarship.org/uc/item/8x51z8rb
Autor:
Kathryn Finch Mileham, Cassadie Moravek, Andrew S. Kennedy, Thomas S. Uldrick, E. Claire Dees, Caroline Schenkel, Scot Ebbinghaus, S. Percy Ivy, Jamie Renee Brewer, Atiqur Rahman, R. Donald Harvey, Vishal Bhatnagar, Elizabeth Ness
Publikováno v:
Clin Cancer Res
Purpose: Washout periods and concomitant medication exclusions are common in cancer clinical trial protocols. These exclusion criteria are often applied inconsistently and without evidence to justify their use. The authors sought to determine how was
Autor:
Xiaoyun Nicole Li, Thomas Jemielita, Cong Chen, S. Peter Kang, Meihua Wang, Chen Hu, Scot Ebbinghaus, Nageatte Ibrahim, James R. Anderson
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-10 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background In oncology clinical development, objective response rate, disease control rate and early tumor size changes are commonly used as efficacy metrics for early decision-making. However, for immunotherapy trials, it is unclear whether these ea
Autor:
Julie A. Stone, Jiannan Kang, Kapil Mayawala, Jonathan W. Riess, Scot Ebbinghaus, Lokesh Jain, Keaven M. Anderson, David C. Turner, Andrew G. Robinson, Anna Georgieva Kondic, Vikram Sinha, Dinesh P. de Alwis, Edward B. Garon
Publikováno v:
Clinical Cancer Research. 24:5841-5849
Purpose: To investigate the relationship of pembrolizumab pharmacokinetics (PK) and overall survival (OS) in patients with advanced melanoma and non–small cell lung cancer (NSCLC). Patients and Methods: PK dependencies in OS were evaluated across t
Autor:
Jianmin Long, Jacob Schachter, Ewan Brown, Antoni Ribas, Laurent Mortier, Christoph Hoeller, Scot Ebbinghaus, Adil Daud, Nageatte Ibrahim, Omid Hamid, A. Arance, Marcus O. Butler, Caroline Robert, Euan Walpole, F. Stephen Hodi
Publikováno v:
British Journal of Cancer
Background Mucosal melanoma is an aggressive melanoma with poor prognosis. We assessed efficacy of pembrolizumab in patients with advanced mucosal melanoma in KEYNOTE-001 (NCT01295827), −002 (NCT01704287), and −006 (NCT01866319). Methods Patients
Autor:
Marcelo Garrido, Valeriy Breder, Erluo Chen, Jennifer J. Knox, Scot Ebbinghaus, Thomas Yau, Bruno Daniele, Abby B. Siegel, Sadahisa Ogasawara, Yee Chao, Philippe Merle, Mohamed Bouattour, Julien Edeline, Ann-Lii Cheng, Ho Yeong Lim, Richard S. Finn, Masatoshi Kudo, Stephen L. Chan, Baek-Yeol Ryoo, Andrew X. Zhu
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 38(3)
PURPOSE Pembrolizumab demonstrated antitumor activity and safety in the phase II KEYNOTE-224 trial in previously treated patients with advanced hepatocellular carcinoma (HCC). KEYNOTE-240 evaluated the efficacy and safety of pembrolizumab in this pop
Autor:
Gontran Verset, James Lee, Sadahisa Ogasawara, Suresh Ratnam, Vittorina Zagonel, Angela Tatiana Alistar, Scot Ebbinghaus, Robin Kate Kelley, Chris Verslype, Daniel H. Palmer, Masatoshi Kudo, Olivier Rosmorduc, Ivan Borbath, Alan Weiss, Atisha Manhas, Carmine Pinto, Yutaka Sasaki, Yvonne Sada, Bruno Daniele, Laetitia Fartoux, Karl-Heinz Weiss, Daneng Li, Andrea L. Webber, Timothy Cannon, Gina M. Vaccaro, Per I Stal, Timothy Larson, Mukul Gupta, Jean-Frédéric Blanc, Simone I. Strasser, Kazushi Numata, Tatsuya Yamashita, David Cosgrove, Allen Lee Cohn, Ki Chung, Junshui Ma, Julien Edeline, Yoshivasu Karino, Jennifer J. Knox, Joerg Trojan, Debashis Sarker, Nevena Damjanov, Hans Van Vlierberghe, Richard S. Finn, Stephen L. Chan, Andreas Kaubisch, Jamil Asselah, Andrew X. Zhu, Magnus Rizell, Jena-Luc Van Laethem, Robert A. Ramirez, Mark Karwal, Gulam Abbas Manji, Ann-Lii Cheng, Arndt Vogel, Andrew Scott Paulson, Stéphane Cattan, Abby B. Siegel, Benjamin M. Parsons
Publikováno v:
The Lancet Oncology. 19:940-952
Summary Background Immune checkpoint blockade therapy has shown promising results in patients with advanced hepatocellular carcinoma. We aimed to assess the efficacy and safety of pembrolizumab in this patient population. Methods KEYNOTE-224 is a non
Autor:
Jin Zhang, Jeffrey S. Weber, James R. Anderson, Anthony M. Joshua, Adil Daud, Scot Ebbinghaus, Richard F. Kefford, Richard W. Joseph, Amita Patnaik, Peter Hersey, Wen-Jen Hwu, Omid Hamid, Caroline Robert, Tara C. Gangadhar, Antoni Ribas, Scott J. Diede, F. Stephen Hodi, Hassane M. Zarour, Roxana S. Dronca, Jedd D. Wolchok
Publikováno v:
Journal of Clinical Oncology. 36:1668-1674
Purpose Pembrolizumab provides durable antitumor activity in metastatic melanoma, including complete response (CR) in about 15% of patients. Data are limited on potential predictors of CR and patient disposition after pembrolizumab discontinuation af
Autor:
Kendall Lee Stevinson, C. Lance Cowey, Jenny Black-Shinn, Jennifer Frytak, Scot Ebbinghaus, Frank Xiaoqing Liu, Marley Boyd
Publikováno v:
Journal of Immunotherapy (Hagerstown, Md. : 1997)
The programmed death-1 inhibitor pembrolizumab has demonstrated efficacy and safety in clinical trials for treating advanced (unresectable/metastatic) melanoma. We investigated the real-world utilization of pembrolizumab and associated patient outcom